Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
Open Access
- 1 September 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 10, 375-383
- https://doi.org/10.2147/DMSO.S130810
Abstract
Background: Lipodystrophy (LD; non-human immunodeficiency virus [HIV]-associated) syndromes are a rare body of disorders for which true prevalence is unknown. Prevalence estimates of rare diseases are important to increase awareness and financial resources. Current qualitative and quantitative estimates of LD prevalence range from ~0.1 to 90 cases/million. We demonstrate an approach to quantitatively estimate LD prevalence (all, generalized, and partial) through a search of 5 electronic medical record (EMR) databases and 4 literature searches. Methods: EMR and literature searches were conducted from 2012 to 2014. For the EMR database searches (Quintiles, IMS LifeLink, General Electric Healthcare, and Humedica EMR), LD cases were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 272.6 (United Kingdom General Practice Research Database used other diagnostic codes to identify LD) plus additional LD-associated clinical characteristics (patients with HIV or documented HIV treatment were excluded). Expert adjudication of cases was used for the Quintiles database only. Literature searches (PubMed and EMBASE) were conducted for each of the 4 major LD subtypes. Prevalence estimates were determined by extrapolating the total number of cases identified for each search to the database population (EMR search) and European population (literature search). Results: The prevalence range of all LD across all EMR databases was 1.3–4.7 cases/million. For the adjudicated Quintiles search, the estimated prevalence of diagnosed LD was 3.07 cases/million (95% confidence interval [CI], 2.30–4.02), 0.23 cases/million (95% CI, 0.06–0.59) and 2.84 cases/million (95% CI, 2.10–3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively. For all literature searches, the prevalence of all LD in Europe was 2.63 cases/million (0.96 and 1.67 cases/million for GL and PL, respectively). Conclusion: LD prevalence estimates are at the lower range of previously established numbers, confirming that LD is an ultra-rare disease. The establishment of diagnostic criteria and coding specific to the 4 major LD subtypes and future studies/patient registries are needed to further refine our estimates.Keywords
This publication has 17 references indexed in Scilit:
- The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2016
- Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoidArchiv für dermatologische Forschung, 2015
- A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseasesOrphanet Journal of Rare Diseases, 2014
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyEuropean Heart Journal, 2014
- Novel Forms of LipodystrophyDiabetes Care, 2013
- Diagnosis, misdiagnosis, and associated diseases of achalasia in children and adolescents: a twelve-year single center experiencePediatric Surgery International, 2012
- Lipodystrophies: Genetic and Acquired Body Fat DisordersJournal of Clinical Endocrinology & Metabolism, 2011
- Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosisQJM: An International Journal of Medicine, 2011
- Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial LipodystrophyMedicine, 2004
- LipodystrophiesThe American Journal of Medicine, 2000